Abstract: Bradykinin antagonists and their physiologically tolerated salts are suitable for the treatment or prophylaxis of virus diseases.

Abstract: Urea derivates are disclosed having the formula (I). ##STR1## in which A, B, W, Z, R, R.sup.1, R.sup.2, R.sup.3 and r have the meaning given in the description, as well as a process for preparing the same and their use as inhibitors of thrombocyte aggregation, carcinom cell metastasis and osteoclast binding to bone surface.

Abstract: The present invention relates to novel substituted amino compounds of the formula I:R.sup.1 -(A).sub.a -(B).sub.b -(D).sub.c -(CH.sub.2).sub.m -N(R.sup.2)-(CH.sub.2).sub.n -R.sup.3as defined in the present application, and to a process for preparing such compounds. The invention also includes pharmaceutical compositions containing the present compounds, and the preparation of such compositions. The invention also relates to the use of the present compounds as inhibitors of blood-platelet aggregation, formation of metastases by carcinoma cells, and the binding of osteoclasts to bone surfaces, in the treatment of hosts in need thereof.

Abstract: The invention concerns heterocyclic compounds of the general formula (I) in which A, B, R, R.sup.2, R.sup.3, W, Y, Z.sup.1, Z.sup.2 and r are as defined in the description, methods of preparing them and their use as inhibitors of thrombocyte aggregation, the metastization of carcinoma cells and the binding of osteoclasts on bone surfaces.

Abstract: Peptides of the formula IA-B-C-E-F-K-P-G-M-F'-I (I),wherein the terms A, B, C, E, F, K, P, G, M, F', and I are defined in the specification, have bradykinin antagonist action. Their therapeutic utility includes all pathological states which are mediated, caused or supported by bradykinin and bradykinin-related peptides.

Abstract: Peptides with an insulin-like action, of formula I: ##STR1## in which G is a hydrogen atom, an amino add residue, or a monosubstituted or polysubstituted amino acid; D is an amino acid residue, a phosphoamino acid residue, a monosaccharide residue, or a covalent bond; E is --NH--(CH.sub.2).sub.n --NR.sup.5.sub.2, a glycerol residue, or --NH--(CH.sub.2).sub.p --R.sup.6 --R.sup.7 ; R.sup.1 is (C.sub.1 -C.sub.4)-alkyl or .dbd.O; R.sup.2 is a sulfhydryl protecting group, (C.sub.1 -C.sub.3)-alkyl, or a hydrogen atom; R.sup.3 and R.sup.4, independently of one another, are a hydrogen atom or methyl; R.sup.5, each being identical or different, is a hydrogen atom, 1 to 6 monosaccharide residues, or 1 to 6 monosubstituted or polysubstituted monosaccharide residues; R.sup.6 is O PO.sub.4 H, PO.sub.2 H, NHCOO, S or OCOO; R.sup.

Abstract: Peptides of the formula IZ-P-A-B-C-E-F-K-(D)Q-G-M-F'-I (I)and the physiologically tolerated salts thereof, are described.They have an excellent bradykinin-antagonistic action.They are obtained by reacting reacting a fragment with a C-terminal free carboxyl group or its activated derivative with a corresponding fragment with an N-terminal free amino group or assembling the peptide stepwise, where appropriate eliminating in the compound obtained in this way one or more protective groups introduced temporarily to protect other functionalities, and where appropriate converting the compounds of the formula I obtained in this way into the physiologically tolerated salt thereof.

Abstract: The present invention relates to compounds of the general formula I ##STR1## in which R, R.sup.1 to R.sup.4, r, Y, Z and W are defined as indicated in the description, a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Abstract: A process is described for preparing aminoethylglycine from diaminoethane and glyoxylic acid by means of reductive amination.

Abstract: Phenylimidazolidine derivatives of the general formula I ##STR1## in which, for example, Y denotes --CH.sub.2 --CH.sub.2 --CO--r denotes 0 to 3Z denotes oxygenW denotes hydroxylR.sup.1 denotes --NH--C(.dbd.NH)--NH.sub.2R, R.sup.2, R.sup.3 denote hydrogenR.sup.4 denotes --CO--NHR.sup.5,where --NH--R.sup.5 represents an .alpha.-amino acid radical, have useful pharmacological properties such as inhibition of platelet aggregation and osteoclast binding to the bone surfaces.

Abstract: Novel compounds of the formula I ##STR1## in which X is an anion, and a process for the preparation thereof, are described. Compounds of the formula I are used as coupling reagents in peptide synthesis.

Abstract: The invention relates to new compounds of the formula ##STR1## in which R.sup.1 denotes (C.sub.1 -C.sub.8)-alkyl, R.sup.2 denotes an amino acid residue which is protected with a urethane protective group which can be eliminated with weak acid or base, or denotes an amino protective group which can be eliminated with weak acid or base, R.sup.3 denotes hydrogen or (C.sub.1 -C.sub.4)-alkyl, and Y.sup.1 -Y.sup.9 denote identical or different radicals hydrogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or --O--(CH.sub.2).sub.n --COOH (with n=1 to 6), with one of these radicals being --O--(CH.sub.2).sub.n --COOH, or Y.sup.1, Y.sup.2 and Y.sup.5 -Y.sup.9 denote identical or different radicals hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkoxy, Y.sup.3 denotes hydrogen or (C.sub.1 -C.sub.8)-alkoxy and Y.sup.4 denotes --(CH.sub.2).sub.n --COOH or --NH--CO--(CH.sub.2).sub.n --COOH (with n=1 to 6).

Abstract: A rapidly cleavable substrate for HIV protease Hepta- to nona-peptides of the formulaA--B--C--D--E--Opr--F--G--H,in which A is absent or represents Val, Ile or Thr, B denotes Ser, Thr or Phe, D denotes Asp or Ala, E denotes Tyr or Phe, Opr denotes 5-oxaproline, F denotes Ile, Leu, Val, Thr or Gln, G denotes Val, Ile, Ser or Arg, and H is absent or represents Gln, Glu, Pro or Thr, as well as the salts thereof are used for locating and detecting HIV protease and for testing possible inhibitors of HIV protease. They are prepared by known methods of peptide chemistry, preferably by means of solid-phase synthesis.

Abstract: The invention relates to peptides of the formulaR.sup.N --L--N--B.sup.2 --R.sup.C (I)in which R.sup.N denotes an acyl radical, L denotes a radical of a lipophilic, neutral .alpha.-amino acid, N denotes a radical of an neutral .alpha.-amino acid, B.sup.2 denotes the radical of a basic .alpha.-amino acid, and R.sup.C denotes an amido radical; a process for their preparation, agents containing these peptides, and their use.

Abstract: The invention relates to new compounds of the formula ##STR1## in which R.sup.1 denotes (C.sub.1 -C.sub.8)-alkyl or optionally substituted (C.sub.6 -C.sub.14)-aryl, R.sup.2 denotes hydrogen or an amino acid residue which is protected by an amino protective group which can be cleaved off with weak acid or base, R.sup.3 denotes hydrogen or (C.sub.1 -C.sub.4)-alkyl, and Y.sup.1 -Y.sup.9 denote identical or different radicals hydrogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or -O-(CH.sub.2).sub.n -COOH (with n=1 to 6), one of these radicals being -O-(CH.sub.2).sub.n -COOH. A process for the preparation thereof and the synthesis of peptide amides by means of a solid phase method using these new compounds (spacers) are described.

Abstract: The invention relates to new peptides of the formula ##STR1## in which X, A, B, C, N', E, F, G and Z have the meanings indicated in the description, to a process for their preparation, to agents containing them, and to their use.